Canakinumab

Anti–IL-1β monoclonal antibody

Response rate
High (RCT confirmed)
Onset
Days–weeks
Route
SC 150mg every 4–8 weeks
Line
2nd
IgM effect
No effect

Evidence summary

Directly neutralises IL-1β with long half-life. The only RCT in Schnitzler demonstrated sustained efficacy.

Molecular targets (1)

MoleculeRoleExpressionEvidence
IL-1βCentral pathogenic driverElevatedestablished

Sources (2)

H1de Koning HD et al. (2013) Canakinumab efficacy (9-month trial) · Ann Rheum DisDOI ↗
B2de Koning HD et al. (2015) IL-1β centrality via canakinumab trial · Arthritis Res TherDOI ↗